MCLA-129 Clinical Trials

2 recruitingDrug

Phase 12Phase 22

Filters

Status

RecruitingNot yet recruitingEnrolling by invitationActive, not recruiting

Sex

MaleFemale

Your Age

Shows trials you qualify for by age

Phase

Phase 1Phase 2Phase 3Phase 4Early Phase 1Not Applicable

Study Type

InterventionalObservational

Country

United StatesCanadaUnited KingdomAustraliaGermanyFranceSpainItaly

Related Interventions

Ensartinib5

Showing 1–2 of 2 trials

Recruiting

Phase 1Phase 2

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Solid Advanced Tumor

Betta Pharmaceuticals Co., Ltd.164 enrolled1 locationNCT07448116

Recruiting

Phase 1Phase 2

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Solid Tumor

Betta Pharmaceuticals Co., Ltd.400 enrolled87 locationsNCT04930432

ClinicalTrialsFinder

Helping patients and researchers find recruiting clinical trials. Updated regularly from ClinicalTrials.gov and ANZCTR.

Browse

Browse Conditions
Browse Drugs
Browse Locations
Browse Institutions
Search Trials
Get Trial Alerts

Resources

Clinical Trial Guides
FAQ
About Us
Contact
ClinicalTrials.gov
ANZCTR

Data Source

Trial data sourced from ClinicalTrials.gov and ANZCTR (Australian New Zealand Clinical Trials Registry)

Updated regularly to reflect the latest trial information

Medical Disclaimer: This site is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making decisions about participating in a clinical trial. Trial information may change; verify details directly with the trial sponsor or at the relevant registry (ClinicalTrials.gov or ANZCTR).

|

Privacy Policy Terms of Service

Data provided by ClinicalTrials.gov & ANZCTR